130 related articles for article (PubMed ID: 3666002)
1. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
[TBL] [Abstract][Full Text] [Related]
2. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
Muss H; Bundy BN; DiSaia PJ; Twiggs LB
Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
[No Abstract] [Full Text] [Related]
3. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
4. Teniposide in refractory ovarian cancer: a phase II study.
Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
[No Abstract] [Full Text] [Related]
5. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
7. [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Jankowski RP; Vahrson H
Med Klin; 1977 Dec; 72(49):2122-6. PubMed ID: 337083
[TBL] [Abstract][Full Text] [Related]
8. Teniposide (VM-26) in patients with non-squamous-cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group.
Muss HB; Bundy BN; Given FT; Stehman FB
Am J Clin Oncol; 1990 Apr; 13(2):117-8. PubMed ID: 2316480
[TBL] [Abstract][Full Text] [Related]
9. Teniposide (VM-26) in ovarian cancer: a review.
van der Gaast A; Splinter TA
Semin Oncol; 1992 Apr; 19(2 Suppl 6):95-7. PubMed ID: 1411643
[TBL] [Abstract][Full Text] [Related]
10. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.
Pfeiffer P; Cold S; Bertelsen K; Panduro J; Sandberg E; Rose C
Gynecol Oncol; 1990 May; 37(2):230-3. PubMed ID: 2344968
[TBL] [Abstract][Full Text] [Related]
11. Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia.
Shimizu H; Frankel LS; Culbert SJ
Am J Pediatr Hematol Oncol; 1987; 9(3):239-41. PubMed ID: 3479027
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
13. VM-26 in colorectal carcinoma: a Southwest Oncology Group study.
Oishi N; Fleming TR; Laufman L; Ungerleider JS; Natale RB; Einstein AB; Von Hoff DD; Macdonald JS
Invest New Drugs; 1990 Feb; 8(1):93-5. PubMed ID: 2188930
[TBL] [Abstract][Full Text] [Related]
14. [Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
Chatelut E; Canal P; De Forni M; Chevreau C; Houin G; Bugat R
Bull Cancer; 1989; 76(8):893-6. PubMed ID: 2620120
[No Abstract] [Full Text] [Related]
15. Phase II study of teniposide in small cell carcinoma of the lung.
Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
[TBL] [Abstract][Full Text] [Related]
16. Teniposide in the treatment of non-small cell lung carcinoma.
Giaccone G; Donadio M; Ferrati P; Bonardi G; Ciuffreda L; Bagatella M; Calciati A
Cancer Treat Rep; 1987 Jan; 71(1):83-5. PubMed ID: 3024829
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
18. Teniposide is not effective in chronic lymphocytic leukemia.
Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
[TBL] [Abstract][Full Text] [Related]
19. [VM-26 and VP-16 salvage therapy for refractory germinal testicular cancers].
Miki T; Tomooka Y; Yoshimura K; Maeda O; Saiki S; Kinouchi T; Kuroda M; Usami M; Kotake T
Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1609-16. PubMed ID: 2593435
[TBL] [Abstract][Full Text] [Related]
20. [VM-26 and cytosine arabinoside in the treatment of acute refractory lymphoblastic leukemia in adults].
Marín P; Grañena A; Carreras E; Sierra J; Olivé MT; Rozman C
Sangre (Barc); 1984; 29(4-A):399-404. PubMed ID: 6594782
[No Abstract] [Full Text] [Related]
[Next] [New Search]
